|
12/05/2021 |
CIMAvax-EGF in different maintenance schemes |
CIM |
Registered outdated |
|
18/06/2021 |
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
CIM |
Registered outdated |
|
30/06/2021 |
Itolizumab-Plasmapheresis in patients with COVID-19 |
CIM |
Registered |
|
21/06/2023 |
VSSPs in renal carcinoma. |
CIM |
Registered |
|
21/05/2021 |
Nimotuzumab in COVID-19 |
CIM |
Registered |
|
20/10/2021 |
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT |
CIM |
Registered |
|
21/03/2022 |
Post EUA study of Itolizumab in COVID-19 |
CIM |
Registered outdated |
|
20/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease |
CIM |
Registered |
|
22/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
CIM |
Registered |
|
16/08/2023 |
Her1 vaccine in metastatic colon and prostate cancer |
CIM |
Registered |
|
27/02/2024 |
Jusvinza in adult patients with Rheumatoid Arthritis from Camaguey and Eastern Provinces |
CIGB_IB |
Registered |
|
2012-06-08 |
HeberPAG® in Mycosis Fungoides (MYFIC Study) |
CIGB |
Registered |
|
2012-09-12 |
Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary vaccination series |
CIGB |
Registered |
|
2012-10-12 |
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
CIGB |
Registered |
|
2013-01-17 |
Intravenous CIGB-128-A in patients with brain tumors (BRATINC Study) |
CIGB |
Registered |
|
2013-01-18 |
Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study) |
CIGB |
Registered |
|
2013-01-18 |
Biodistribution of CIGB-300 in cervical cancer (CERVIFARM-300-II Study) |
CIGB |
Registered |
|
2013-01-30 |
Safety with interferon in skin carcinomas (SCIENCE study) |
CIGB |
Registered |
|
2013-02-01 |
Squamous cell carcinoma interferons (CECIN study) |
CIGB |
Registered |
|
2013-02-01 |
Interferon Combination in basal cell carcinoma (InCarbacel-V study) |
CIGB |
Registered |
